Linagliptin
Who holds supplier records for Linagliptin? 30 organisations hold a current record for Linagliptin: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 1 of them holds a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (20), China (5), Netherlands (1) and Poland (1); not recorded for 3.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Linagliptin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/linagliptin
Reading the evidence
- 30 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
20 of the 27 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 17 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Linagliptin expires 8 Dec 2037. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (30)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Linagliptin. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Alembic Pharmaceuticals LimitedIndia Company GMP cert on recordActive DMF 31452, 43882 · latest filing Mar 2026
- Biocon LimitedIndiaActive DMF 35771, 41475 · latest filing Mar 2025
- HONOUR LAB LTDIndia Company GMP cert on recordActive DMF 28877, 28878 · latest filing Jan 2015
- MSN PHARMACHEM PRIVATE LTDIndiaActive DMF 28098, 42033 · latest filing May 2025
- Zhejiang Huahai Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on recordActive DMF 28766 · latest filing Nov 2014
- ALIVUS LIFE SCIENCES LTDIndia Company GMP cert on recordActive DMF 27907 · latest filing Mar 2014
- APITORIA PHARMA PRIVATE LTDIndia Company GMP cert on recordActive DMF 28940 · latest filing Jan 2015
- BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTDChinaActive DMF 28404 · latest filing Jun 2014
- CENTAUR PHARMACEUTICALS PVT LTDIndia Company GMP cert on recordActive DMF 37163 · latest filing May 2022
- CHIERON ACTIVE INGREDIENTS PRIVATE LTDIndiaActive DMF 35748 · latest filing Mar 2021
- Ctx LifesciencesIndiaActive DMF 42793 · latest filing Oct 2025
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 28767 · latest filing Jan 2015
- FUXIN LONG RUI PHARMACEUTICAL CO LTDActive DMF 33098 · latest filing Sept 2018
- Granules India LimitedIndia Company GMP cert on recordActive DMF 39130 · latest filing Jan 2024
- HARMAN FINOCHEM LTDIndia Company GMP cert on recordActive DMF 38819 · latest filing Sept 2023
- LEE PHARMA LTDIndia Company GMP cert on recordActive DMF 36923 · latest filing Sept 2023
- Macleods Pharmaceuticals Ltd.India Company GMP cert on recordActive DMF 32498 · latest filing Apr 2018
- MATRIX PHARMACORP PRIVATE LTDIndiaActive DMF 28748 · latest filing Oct 2014
- MOREPEN LABORATORIES LTDIndia Company GMP cert on recordActive DMF 34162 · latest filing Oct 2019
- OPTIMUS DRUGS PRIVATE LTDIndiaActive DMF 36650 · latest filing Apr 2022
- RUYUAN HEC PHARM CO LTDActive DMF 28785 · latest filing Dec 2014
- Shandong New Time Pharmaceutical Co LtdCompany GMP cert on recordActive DMF 41899 · latest filing Sept 2025
- Shanghai Wonder Pharmaceutical Co., LtdChinaActive DMF 32386 · latest filing Jan 2018
- Sun Pharmaceutical Industries LimitedIndia Company GMP cert on recordActive DMF 28971 · latest filing Feb 2015
- TAPI NL BVNetherlandsActive DMF 28769 · latest filing Nov 2014
- Viyash Scientific LtdIndia Company GMP cert on recordActive DMF 39336 · latest filing Jul 2024
- Wisdom Pharmaceutical Co., LtdChinaActive DMF 31294 · latest filing Dec 2016
- YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTDChinaActive DMF 42041 · latest filing May 2025
- Zakłady Farmaceutyczne Polpharma S.A.Poland Company GMP cert on recordActive DMF 29844 · latest filing Sept 2015
- Zydus Lifesciences LimitedIndia Company GMP cert on recordActive DMF 29017 · latest filing Jan 2015
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (1)
Certificates of Suitability on the EDQM register for Linagliptin, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. Taizhou | CN | CEP 2026-380 - Rev 00 Linagliptin, Process II, micronised and non-micronised | Sept 2026 | Inspected May 2026 Italy |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (1)
Organisations whose Type II DMFs for Linagliptin are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- Viwit Pharmaceutical Co., Ltd.China · Inactive DMF 29692 · filed Aug 2015
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (9 listed products contain Linagliptin). The latest listed patent expires 8 Dec 2037. The latest listed exclusivity runs to 20 Dec 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor used as an oral hypoglycemic agent for the treatment of type 2 diabetes. It works by increasing the levels of incretin hormones, which inhibit glucagon release and increase insulin secretion.
Chemical identity
- IUPAC name
- 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
- Canonical SMILES
- CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
- InChIKey
- LTXREWYXXSTFRX-QGZVFWFLSA-N
- Synonyms
- bi 1356, bi 1356 bs, bi-1356, bi-1356-bs, bi-1356bs, bi1356, bs 1356 bs, bs-1356-bs, glyxambi component linagliptin, trajenta, trazenta, trijardy xr component linagliptin
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Dipeptidyl Peptidase 4 Inhibitor
- Mechanism of action
- Dipeptidyl Peptidase 4 Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Linagliptin?
30 organisations hold an active US FDA Type II Drug Master File or a CEP for Linagliptin: Alembic Pharmaceuticals Limited (India), Biocon Limited (India), HONOUR LAB LTD (India), MSN PHARMACHEM PRIVATE LTD (India), Zhejiang Huahai Pharmaceutical Co., Ltd. (China), ALIVUS LIFE SCIENCES LTD (India), APITORIA PHARMA PRIVATE LTD (India) and BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTD (China), and 22 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Linagliptin Drug Master Files are active?
Alembic Pharmaceuticals Limited (DMF 31452, 43882), Biocon Limited (DMF 35771, 41475), HONOUR LAB LTD (DMF 28877, 28878), MSN PHARMACHEM PRIVATE LTD (DMF 28098, 42033), Zhejiang Huahai Pharmaceutical Co., Ltd. (DMF 28766), ALIVUS LIFE SCIENCES LTD (DMF 27907), APITORIA PHARMA PRIVATE LTD (DMF 28940) and BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTD (DMF 28404) and 22 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Linagliptin records mean?
1 organisation has only inactive Type II DMFs for Linagliptin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Linagliptin have a European Certificate of Suitability?
Yes. 1 organisation holds a valid CEP for Linagliptin on the EDQM register, including ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. Taizhou (CN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
Does the FDA Orange Book list patents for products containing Linagliptin?
Yes. The latest patent listed for an approved US product containing Linagliptin expires 8 Dec 2037, across 9 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Linagliptin supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Linagliptin?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.